Dana Investment Advisors Inc. Makes New Investment in Zymeworks Inc. $ZYME

Posted by Geri Gentry on May 19th, 2026

Dana Investment Advisors Inc. acquired a new position in Zymeworks Inc. (NASDAQ:ZYME – Free Report) during the fourth quarter, HoldingsChannel reports. The institutional investor acquired 48,318 shares of the company’s stock, valued at approximately $1,272,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rubric Capital Management LP boosted its holdings in Zymeworks by 8.6% in the second quarter. Rubric Capital Management LP now owns 4,710,551 shares of the company’s stock valued at $59,117,000 after acquiring an additional 372,107 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Zymeworks by 8.1% in the 4th quarter. Vanguard Group Inc. now owns 2,328,727 shares of the company’s stock worth $61,315,000 after purchasing an additional 174,293 shares during the period. Vestal Point Capital LP boosted its stake in shares of Zymeworks by 53.5% during the 3rd quarter. Vestal Point Capital LP now owns 1,765,000 shares of the company’s stock valued at $30,146,000 after purchasing an additional 615,000 shares in the last quarter. Millennium Management LLC increased its position in shares of Zymeworks by 851.6% during the third quarter. Millennium Management LLC now owns 1,104,813 shares of the company’s stock valued at $18,870,000 after buying an additional 988,711 shares during the period. Finally, Capricorn Fund Managers Ltd bought a new position in Zymeworks in the fourth quarter worth about $26,931,000. Institutional investors own 92.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ZYME shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a report on Monday, April 20th. HC Wainwright raised their target price on Zymeworks from $32.00 to $46.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Wells Fargo & Company upped their price target on Zymeworks from $33.00 to $34.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Truist Financial upgraded Zymeworks to a “strong-buy” rating in a report on Monday, April 27th. Finally, Leerink Partners raised their price objective on Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a research report on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Zymeworks has a consensus rating of “Moderate Buy” and an average target price of $38.00.

View Our Latest Research Report on Zymeworks

Zymeworks Stock Performance

Shares of ZYME opened at $24.43 on Tuesday. Zymeworks Inc. has a fifty-two week low of $11.02 and a fifty-two week high of $29.75. The firm’s 50-day simple moving average is $25.61 and its two-hundred day simple moving average is $24.36. The stock has a market cap of $1.78 billion, a PE ratio of -17.83 and a beta of 1.20.

Zymeworks (NASDAQ:ZYME – Get Free Report) last released its earnings results on Tuesday, March 31st. The company reported ($0.59) earnings per share (EPS) for the quarter. The business had revenue of $2.41 million for the quarter. Zymeworks had a negative net margin of 126.92% and a negative return on equity of 37.97%. Equities research analysts predict that Zymeworks Inc. will post 1.64 EPS for the current year.

Zymeworks declared that its board has initiated a stock repurchase program on Thursday, May 14th that authorizes the company to repurchase $125.00 million in shares. This repurchase authorization authorizes the company to buy up to 7% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Zymeworks Company Profile

(Free Report)

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.